AGENE RES INST CO LTD has a total of 15 patent applications. Its first patent ever was published in 1998. It filed its patents most often in United States, Australia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, measurement and pharmaceuticals are NAT INST OF BIOMEDICAL INNOVATION HEALTH & NUTRITION, NEUROGENETICS INC and UNIV PORTSMOUTH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | Australia | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | EPO (European Patent Office) | 2 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Measurement | |
#3 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Analysing materials | |
#3 | Measuring microorganism processes | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Shimamoto Akira | 13 |
#2 | Furuichi Yasuhiro | 13 |
#3 | Kitao Saori | 11 |
#4 | Nomoto Akio | 2 |
#5 | Isoyama Tsuyoshi | 2 |
#6 | Kuge Shusuke | 2 |
#7 | Nishikawa Kaori | 2 |
Publication | Filing date | Title |
---|---|---|
WO0222812A1 | Methods of assaying or screening compound via detection of nuclear transport receptor inhibition by hepatitis c virus core protein | |
AU6731300A | Nuclear localized recq5 type dna helicase | |
WO0111089A1 | Novel method for screening compound for preventing or treating liver cell injury caused by hepatitis c virus and compound obtained by this method | |
US7081522B2 | Gene causative of Rothmund-Thomson syndrome and gene product | |
US6335435B1 | Human gene RecQ4 encoding helicase |